David Eugene Pereira

US Patent:

6670323, Dec 30, 2003

Filed:

Nov 10, 2000

Appl. No.:

09/709914

Inventors:

Douglas L. Looker - Lafayette CO
Izydor Z. Apostol - Boulder CO
Eric A. Brucker - Evergreen CO
Michael P. Doyle - Boulder CO
David L. Foster - Lafayette CO
Christopher B. Glascock - Louisville CO
James C. Hartman - Boulder CO
Geoffrey F. Lee - Boulder CO
Douglas D. Lemon - Louisville CO
Edwin G. Moore - Boulder CO
Jane P. Richards - Longmont CO
Michael R. Schick - Louisville CO
Stephen P. Trimble - Boulder CO
David Pereira - Apex NC
Ton-That Hai - Mundelein IL
Kenneth E. Burhop - Longmont CO

Assignee:

Baxter International, Inc. - Deerfield IL
Baxter Healthcare S.A. - Kanton Zurich

International Classification:

C07K 14805

US Classification:

514 6, 535385

Abstract:

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

US Patent:

7211560, May 1, 2007

Filed:

Dec 29, 2003

Appl. No.:

10/747580

Inventors:

Douglas L. Looker - Fort Lupton CO, US
Izydor Z. Apostol - Boulder CO, US
Eric A. Brucker - Evergreen CO, US
Michael P. Doyle - Boulder CO, US
David L. Foster - Lafayette CO, US
Christopher B. Glascock - Louisville CO, US
James C. Hartman - Boulder CO, US
Geoffrey F. Lee - Boulder CO, US
Douglas D. Lemon - Louisville CO, US
Edwin G. Moore - Boulder CO, US
Jane P. Richards - Longmont CO, US
Michael R. Schick - Louisville CO, US
Stephen P. Trimble - Boulder CO, US
David Pereira - Apex NC, US
Ton-That Hai - Mundelein IL, US
Kenneth E. Burhop - Longmont CO, US

Assignee:

Baxter International, Inc. - Deerfield IL
Baxter Healthcare S.A. - Zurich

International Classification:

A61K 35/14

US Classification:

514 6, 530385

Abstract:

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

US Patent:

7754902, Jul 13, 2010

Filed:

May 18, 2006

Appl. No.:

11/437013

Inventors:

David E. Pereira - Apex NC, US
Wade Aumiller - Durham NC, US
Raymond Dagger - Raleigh NC, US

Assignee:

Vanda Pharmaceuticals, Inc. - Rockville MD

International Classification:

C07D 307/87
C07C 2/42
C07F 15/00

US Classification:

549462, 556 32, 585368

Abstract:

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl(p-cymene)].

US Patent:

8097738, Jan 17, 2012

Filed:

May 20, 2010

Appl. No.:

12/783935

Inventors:

David E. Pereira - Apex NC, US
Wade Aumiller - Durham NC, US
Raymond Dagger - Raleigh NC, US

Assignee:

VANDA Pharmaceuticals Inc. - Rockville MD

International Classification:

C07D 307/87
C07C 2/42
C07F 15/00

US Classification:

549462, 556 32, 585368

Abstract:

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl(p-cymene)].

US Patent:

8558017, Oct 15, 2013

Filed:

Dec 12, 2011

Appl. No.:

13/316729

Inventors:

David E. Pereira - Apex NC, US
Wade Aumiller - Durham NC, US
Raymond Dagger - Raleigh NC, US

Assignee:

Vanda Pharmaceuticals, Inc. - Washington DC

International Classification:

C07D 307/87
C07C 2/42
C07F 15/00

US Classification:

549462, 556 32, 585368

Abstract:

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran,deprotonated 1,2-cyclohexanediamino-N,N′-bis(3,5-di-t-butyl-salicylidene) and RuCl(p-cymene)].

US Patent:

20030149307, Aug 7, 2003

Filed:

Oct 15, 2002

Appl. No.:

10/272399

Inventors:

Ton Hai - Round Lake IL, US
Larry Markoski - Champaign IL, US
David Pereira - Apex NC, US
Mark Nordhaus - Antioch IL, US

Assignee:

Baxter International Inc.

International Classification:

C07C217/28
C 07C 2 9/04

US Classification:

564/469000, 564/505000

Abstract:

A two step process for the preparation of polyethylene glycol-bis amine comprising a first step of reacting the terminal hydroxy groups of polyethylene glycol with a halogen substituted aromatic sulfonyl halide in a solvent to form a disubstituted sulfonyl activated polyethylene glycol intermediate. In a second step the intermediate is directly aminated with ammonia to give polyethylene glycol-bis amine.

US Patent:

20100216731, Aug 26, 2010

Filed:

Oct 23, 2008

Appl. No.:

12/739652

Inventors:

David E. Pereira - Apex NC, US
Manish Kanchanbhai Patel - Toronto, CA
Keshav Deo - Vadodara, IN

Assignee:

CEMPRA PHARMACEUTICALS, INC. - Chapel HIll NC

International Classification:

A61K 31/7056
C07H 17/08
A61P 31/04

US Classification:

514 29, 536 74

Abstract:

Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.

US Patent:

20110201566, Aug 18, 2011

Filed:

Oct 24, 2009

Appl. No.:

13/125555

Inventors:

Prabhavathi B. Fernandes - Chapel Hill NC, US
David E. Pereira - Apex NC, US

Assignee:

CEMPRA PHARMACEUTICALS, INC. - Chapel Hill NC

International Classification:

A61K 31/7056
A61P 31/04

US Classification:

514 29

Abstract:

Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.

Address:

103 Lansbrooke Ln, Apex, NC 27502

Phone:

(919)3678748

VIN:

2A4GP54L07R156867

Make:

CHRYSLER

Model:

TOWN AND COUNTRY

Year:

2007